Table 1.
Baseline demographics and clinical assessment scores for the healthy controls, RA and AS patients.
Table 2.
ELISA technical performance.
Figure 1.
The level of the cartilage degradation and connective tissue inflammation in RA patients (n = 47) and healthy controls (n = 56).
A) Cartilage degradation measured by C2M in serum. B) Connective tissue degradation measured by C3M in serum. C) The diagnostic utility depicted as area under the curve (AUC), odds ratio (OR), sensitivity, specificity and likelihood ratio (LR). Cut-off values were set as 1 SD above the mean of the healthy controls. Comparison of RA patients and controls was performed on log transformed data with student’s t-test. Results are shown as geometric mean with 95% CI. Diagnostic utility was calculated by a contingency table applying Fisher’s exact test.
Figure 2.
The level of the cartilage degradation and connective tissue inflammation in AS patients (n = 103) and controls (n = 56).
A) Cartilage degradation measured by C2M in serum. B) Connective tissue degradation measured by C3M in serum C) The diagnostic utility depicted as area under the curve (AUC), odds ratio (OR), sensitivity, specificity and likelihood ratio (LR). Cut-off values were set as 1 SD above the mean of the healthy controls. Comparison of AS patients and controls was performed on log transformed data with student’s t-test. Results are shown as geometric mean with 95% CI. Diagnostic utility was calculated by a contingency table applying Fisher’s exact test.
Table 3.
Univariate analysis for C2M and C3M associations with age, disease duration and RA clinical characteristics; Disease activity score (DAS), health assessment questionnaire (HAQ), erythrocyte sedimentation rate (ESR), high sensitive C-reactive protein (CRP), tender joint count (TJC) and swollen joint count (SJC).
Table 4.
Univariate analysis for C2M and C3M associations with age, disease duration and AS clinical characteristics; erythrocyte sedimentation rate (ESR), high sensitive C-reactive protein (CRP), mSASSS and BASDAI.
Table 5.
Clinical predictive utility of the serum markers.